My Malignant Melanoma

Seanty's experiences with Metastatic Malignant Melanoma. Part of Email us direct at

Thursday, 9 June 2011


Not so NICE?

So we have some new effective drugs for MM which have been free to patients during the clinical trials, but back in the real world, I hear they are likely to cost about £75,000 for a course of treatment.

NICE thinks a quality adjusted year of life is worth around £30,000, so the drugs would have to provide at least a couple of years of good quality life to get past NICE (which they don't on average)

Better start the petition now!

Sunday, 5 June 2011


PLX4032/Vemurafenib Phase III trial results

Phase III trial results are in for PLX4032, and they are looking pretty good:  In the study, the risk of death was reduced by 63 percent for people who received vemurafenib compared to those who received chemotherapy. In addition, vemurafenib significantly reduced the risk of the disease getting worse by 74 percent compared to chemotherapy.

Labels: , , ,

Thursday, 2 June 2011


They said it couldnt be done...

Remember when I said that it was unlikely that big pharma companies would collaborate to bring us combinations of the effective new Melanoma treatments? I'm glad to report that Bristol Myers and Roche have proven me wrong with their newly announced collaboration, to combine Roche's BRAF inhibitor PLX4032 (now known as Vemurafenib) with ipilimumab (now known as Yervoy) in Phase III trials.


August 2008   September 2008   October 2008   November 2008   December 2008   January 2009   February 2009   April 2009   May 2009   June 2009   July 2009   August 2009   September 2009   October 2009   November 2009   December 2009   January 2010   February 2010   March 2010   April 2010   May 2010   June 2010   July 2010   August 2010   September 2010   October 2010   November 2010   December 2010   February 2011   March 2011   April 2011   May 2011   June 2011   July 2011   August 2011   September 2011   October 2011   November 2011   December 2011   January 2012   February 2012   March 2012   April 2012   May 2012   June 2012   July 2012   September 2012   November 2012   December 2012   January 2013   May 2013   June 2013   July 2013   August 2013   September 2013   October 2013   December 2013   July 2014   May 2015   July 2015  

This page is powered by Blogger. Isn't yours?

Subscribe to Posts [Atom]